Financials MorphoSys AG

Equities

MOR

DE0006632003

Biotechnology & Medical Research

Real-time Estimate Tradegate 07:32:52 2024-05-28 EDT 5-day change 1st Jan Change
67.92 EUR -0.26% Intraday chart for MorphoSys AG -0.80% +99.71%

Valuation

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Capitalization 1 4,021 3,072 1,139 451 1,278 2,565 - -
Enterprise Value (EV) 1 3,791 2,299 470.7 -116.7 1,278 2,654 2,470 2,284
P/E ratio -38.9 x 31.6 x -2.17 x -2.99 x -6.15 x -6.03 x -32.7 x -161 x
Yield - - - - - - - -
Capitalization / Revenue 56 x 9.37 x 6.34 x 1.62 x 5.36 x 20.9 x 7.89 x 6.04 x
EV / Revenue 52.8 x 7.02 x 2.62 x -0.42 x 5.36 x 21.6 x 7.59 x 5.38 x
EV / EBITDA -37.3 x 64.4 x -1.76 x 0.56 x -5.28 x -14.8 x -24 x -29.9 x
EV / FCF -45.5 x 74.6 x -0.97 x 0.32 x -4.32 x -8.97 x -9.56 x -19.1 x
FCF Yield -2.2% 1.34% -103% 316% -23.2% -11.1% -10.5% -5.25%
Price to Book 10.2 x 4.95 x 4.64 x 2.87 x 26.1 x -14.1 x 4.9 x 3.63 x
Nbr of stocks (in thousands) 31,708 32,739 34,141 34,141 37,593 37,663 - -
Reference price 2 126.8 93.82 33.35 13.21 34.00 68.10 68.10 68.10
Announcement Date 3/18/20 3/15/21 3/16/22 3/15/23 3/13/24 - - -
1EUR in Million2EUR
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net sales 1 71.76 327.7 179.6 278.3 238.3 122.6 325.3 424.8
EBITDA 1 -101.7 35.69 -267.5 -210.2 -241.9 -179.8 -103 -76.3
EBIT 1 -107.9 27.36 -277.6 -220.7 -252.5 -384.7 -81.79 -0.8465
Operating Margin -150.4% 8.35% -154.57% -79.32% -105.96% -313.83% -25.15% -0.2%
Earnings before Tax (EBT) 1 -106.5 22.49 -591.1 -319.6 -190.9 -431.7 -89.21 15.22
Net income 1 -103 97.89 -514.5 -151.1 -189.7 -430.1 -115.7 -31.38
Net margin -143.56% 29.87% -286.47% -54.29% -79.61% -350.87% -35.57% -7.39%
EPS 2 -3.260 2.970 -15.40 -4.420 -5.530 -11.29 -2.083 -0.4239
Free Cash Flow 1 -83.24 30.81 -485.3 -368.6 -296.2 -295.8 -258.3 -119.9
FCF margin -116.01% 9.4% -270.19% -132.48% -124.29% -241.28% -79.42% -28.23%
FCF Conversion (EBITDA) - 86.34% - - - - - -
FCF Conversion (Net income) - 31.48% - - - - - -
Dividend per Share 2 - - - - - - - -
Announcement Date 3/18/20 3/15/21 3/16/22 3/15/23 3/13/24 - - -
1EUR in Million2EUR
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: December 2020 S1 2021 Q4 2022 Q1 2022 Q2 2022 Q3 2022 Q4 2023 Q1 2023 Q2 2023 Q3 2023 Q4 2024 Q1 2024 Q2 2024 Q3 2024 Q4 2025 Q1 2025 Q2
Net sales 1 269.7 52.9 41.5 59.4 95.8 81.6 62.3 53.2 63.8 59 64.69 29.34 32.74 32.97 35.93 -
EBITDA - - - - - - - - - -79.34 - - - - - -
EBIT 1 163.5 -94.3 -68 -55.1 -29.3 -68.37 -69.5 -50.5 -51 -81.4 -382.3 -40.83 -39.51 -39.97 -29.22 -
Operating Margin 60.63% -178.26% -163.86% -92.76% -30.58% -83.79% -111.56% -94.92% -79.94% -137.97% -591% -139.16% -120.69% -121.21% -81.34% -
Earnings before Tax (EBT) 1 - - -122.7 - -123 - -44.4 -74 -119.1 46.7 -312.6 -36.53 -46.53 -50.53 - -
Net income 1 179.8 - -122.7 -235 -122.9 329.4 -44.4 -74 -119.6 48.3 -315 -49.08 -56.95 -61.18 - -
Net margin 66.66% - -295.66% -395.62% -128.29% 403.74% -71.27% -139.1% -187.46% 81.86% -486.87% -167.28% -173.95% -185.55% - -
EPS 2 5.540 -11.16 -3.590 -6.880 -3.600 9.650 -1.300 -2.160 -3.500 1.220 -8.370 -1.203 -1.077 -1.394 -0.6600 -
Dividend per Share 2 - - - - - - - - - - - - - - - -
Announcement Date 8/5/20 3/16/22 5/4/22 8/3/22 11/16/22 3/15/23 5/3/23 8/9/23 11/15/23 3/13/24 4/30/24 - - - - -
1EUR in Million2EUR
Estimates

Balance Sheet Analysis

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net Debt 1 - - - - - 89.3 - -
Net Cash position 1 230 772 668 568 - - 94.7 281
Leverage (Debt/EBITDA) - - - - - -0.4965 x - -
Free Cash Flow 1 -83.2 30.8 -485 -369 -296 -296 -258 -120
ROE (net income / shareholders' equity) -23.3% 19.3% -65.5% -75.1% -184% - -453% -
ROA (Net income/ Total Assets) -19.9% 9.08% -24.4% -6.1% -8.58% -12.9% -8.29% -
Assets 1 517.6 1,078 2,108 2,477 2,211 3,325 1,395 -
Book Value Per Share 2 12.40 19.00 7.190 4.610 1.300 -4.830 13.90 18.80
Cash Flow per Share -2.540 1.060 -14.40 -10.70 - - - -
Capex 1 3.1 4.46 3.81 1.93 2.87 6.76 5.66 5.68
Capex / Sales 4.32% 1.36% 2.12% 0.69% 1.21% 5.51% 1.74% 1.34%
Announcement Date 3/18/20 3/15/21 3/16/22 3/15/23 3/13/24 - - -
1EUR in Million2EUR
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Year-on-year evolution of the Yield

Change in Enterprise Value/EBITDA

Trading Rating
Investor Rating
ESG Refinitiv
B-
More Ratings
Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
8
Last Close Price
68.1 EUR
Average target price
58.71 EUR
Spread / Average Target
-13.78%
Consensus
  1. Stock Market
  2. Equities
  3. MOR Stock
  4. Financials MorphoSys AG